CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it will make multiple presentations, including two oral abstracts, that will be featured at the 35th International Congress of the International Society of Blood Transfusion (ISBT) in Toronto, Canada from June 2nd to June 6th, 2018. ISBT is one of the premier congresses in transfusion medicine.
Cerus will also be hosting a symposium, Pathogen Inactivation Around the World: Setting the Standard for Blood Safety, at ISBT on Tuesday June 5th from 12:00 pm ET to 1:30 pm ET. This symposium will provide a global perspective on the use and evolution of pathogen inactivation. Key opinion leaders from Europe, Latin America and North America will discuss the need for pathogen inactivation, experiences in implementation, and clinical impact, all of which may have unique aspects specific to given regions.
“This year’s ISBT will be the first opportunity for Cerus and investigators from the SPARC study, our European chronic anemia trial in thalassemia patients, to present results. We are looking forward to sharing safety data with the scientific and clinical community,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
Cerus and its clinical partners will present data on an array of topics including the potential operational and cost efficiencies provided by Cerus’ Dual Storage processing set for platelets, the pathogen inactivation efficacy of the INTERCEPT Blood System, and the viability of INTERCEPT-treated platelets stored for seven days.
Key presentations include:
- No INTERCEPT (S-303/Glutathione)-Specific Antibodies Detected in a Phase III, Randomized, Controlled Study to Evaluate Pathogen-Inactivated Red Blood Cells in Thalassemia Major Patients (SPARC), by C Geisen et al.
- Three Years Routine Experience of Manual Production of Double-Dose Buffy Coat Platelets and Pathogen Inactivation System INTERCEPT: Impact on Economy, Blood Safety and Blood Component Quality, by HS Ahlzén and L Larsson
- Amotosalen/UVA Treatment Can Inactivate Klebsiella Pneumoniae in WB-Derived PC To Effective Sterility, After 7 Days of Storage, by N Patel et al.
- Amotosalen-UVA Inactivates High Levels of Treponema Pallidum in Platelet Concentrates Suspended in 100% Plasma, by A Laughhunn et al.
- Inactivation of Trypanosoma Cruzi with Amotosalen/UVA in Platelet Components and Apheresis Plasma, by A Laughhunn, F Buckner, R Gillespie, P Bringmann, and A Stassinopoulos
- In Vitro Characterization of Amotosalen-UVA Platelet Components Stored for 7 Days, by S Yegneswaran et al.
A full list of presentation times, abstracts and details on the symposium can be viewed at http://interceptbloodsystem.com/en/insight/isbt-2018.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.